- Home
- RVPHW vs GLSI Comparison
RVPHW vs GLSI Comparison
Compare RVPHW & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- GLSI
- Stock Information
- Founded
- RVPHW 2018
- GLSI 2006
- Country
- RVPHW United States
- GLSI United States
- Employees
- RVPHW 15
- GLSI N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- RVPHW Health Care
- GLSI Health Care
- Exchange
- RVPHW Nasdaq
- GLSI Nasdaq
- Market Cap
- RVPHW N/A
- GLSI N/A
- IPO Year
- RVPHW N/A
- GLSI 2020
- Fundamental
- Price
- RVPHW $0.03
- GLSI $9.35
- Analyst Decision
- RVPHW
- GLSI Strong Buy
- Analyst Count
- RVPHW 0
- GLSI 1
- Target Price
- RVPHW N/A
- GLSI $38.00
- AVG Volume (30 Days)
- RVPHW 22.4K
- GLSI 41.5K
- Earning Date
- RVPHW 03-14-2025
- GLSI 05-19-2025
- Dividend Yield
- RVPHW N/A
- GLSI N/A
- EPS Growth
- RVPHW N/A
- GLSI N/A
- EPS
- RVPHW N/A
- GLSI N/A
- Revenue
- RVPHW N/A
- GLSI N/A
- Revenue This Year
- RVPHW N/A
- GLSI N/A
- Revenue Next Year
- RVPHW N/A
- GLSI N/A
- P/E Ratio
- RVPHW N/A
- GLSI N/A
- Revenue Growth
- RVPHW N/A
- GLSI N/A
- 52 Week Low
- RVPHW $0.13
- GLSI $9.06
- 52 Week High
- RVPHW $0.15
- GLSI $18.75
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- GLSI 24.33
- Support Level
- RVPHW N/A
- GLSI $9.06
- Resistance Level
- RVPHW N/A
- GLSI $11.37
- Average True Range (ATR)
- RVPHW 0.00
- GLSI 0.76
- MACD
- RVPHW 0.00
- GLSI -0.21
- Stochastic Oscillator
- RVPHW 0.00
- GLSI 6.79
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.